Loading...
NPI 1205063294 · Ramsey, NJ · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Neogenomics Laboratories Inc is a clinical medical laboratory provider located in Ramsey, New Jersey. This profile covers 58 Medicare and 31 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Neogenomics Laboratories Inc |
| Address | 535 E Crescent Ave |
| City | Ramsey |
| State | NJ |
| ZIP | 07446 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 17, 2009 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $3M |
| Medicare | $2.6M |
This provider bills to both Medicare and Medicaid at a similar scale: Total Medicare revenue is $2.6M while Total Medicaid revenue is $3M, so neither payer is exclusive but Medicaid is the slightly larger revenue source. The split suggests the lab operates across payer types rather than as a single-payer specialist, with material exposure to both programs.
NEOGENOMICS LABORATORIES INC has an NPI enumerated on 2009-06-17 (~17 years ago), indicating long-standing participation in federal programs and an established operating history that supports volume in both pathology and molecular services. This tenure is consistent with the breadth of complex codes reported across Medicare and Medicaid.
Medicare billing is concentrated in pathology and cytogenetics/molecular add-on work: the precomputed top 3 Medicare codes (88377, 88305, 88185) account for 54.2% of Medicare revenue, and the code mix includes advanced assays such as 81450 (genomic panel for hematolymphoid neoplasms) and cytogenetic testing (e.g., 88262 and 81206). That combination of surgical pathology, in situ hybridization, flow cytometry add-ons, and targeted genomic panels points to a lab operation focused on oncology and hematopathology services for the Medicare population.
On Medicare, a small set of codes drives a large share of revenue and several show unusually high national standing: 88377 generates $577.7K (23.6% of Medicare revenue) and ranks #12 of 616 (98th percentile; notably above typical national volume), 88305 produces $379.7K (15.5%) and ranks #290 of 14580 (98th percentile; notably above typical national volume), and 88185 contributes $369.8K (15.1%) and ranks #27 of 618 (96th percentile; typical, unremarkable volume). These rankings indicate the provider is a major national volume contributor for multiple high-value pathology codes, not just one outlier.
There are clear statistical outliers among Medicare codes that imply concentrated expertise: 88342 is labeled an extreme outlier (2.3% of Medicare revenue; ranks #92 of 11370, 99th percentile) and 88368 is also an extreme outlier (2.3% of Medicare revenue; ranks #5 of 195, 97th percentile). Those extreme outlier designations, together with above-typical rankings on 88377 and 88305, suggest the lab holds a disproportionately large share of national volume for specific immunohistochemistry and ISH services.
Medicaid revenue is highly concentrated in a small set of codes: the precomputed top 3 Medicaid codes account for 84.1% of Medicaid revenue, led by U0003 at $1.6M (53.9% of Medicaid revenue), followed by 88305 at $683.3K (22.6%) and U0005 at $230K (7.6%). The dominance of U0003/U0005 (high-throughput SARS-CoV-2 NAAT) plus surgical pathology work indicates Medicaid billings are driven heavily by pandemic-related molecular testing and routine pathology services.
State-level competitive standing is mixed but notable: for Medicaid the provider ranks #29 of 127 for U0003 (78th percentile; typical, unremarkable volume) and #14 of 209 for 88305 (94th percentile; typical, unremarkable volume), which positions it as a meaningful in-state participant for both high-throughput infectious testing and surgical pathology. On Medicare the provider’s high national percentiles for multiple pathology codes (for example, 88377 at the 98th percentile and 88305 at the 98th percentile) signal national-scale capacity for selected diagnostic services rather than a low-volume local lab.
From a business risk and opportunity perspective, Medicaid revenue is very dependent on a narrow set of high-volume infectious disease codes (U0003 and U0005) while Medicare revenue is concentrated in a small cluster of pathology/molecular codes (top 3 = 54.2%). That concentration creates operational leverage where the lab’s capacity in high-throughput molecular testing and specialty pathology can be an advantage, but it also implies sensitivity to shifts in demand or reimbursement for those few, high-impact codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
58 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 88377 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a… | 2,180 | $270 | $577.7K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 9,260 | $40 | $379.7K |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 16,810 | $20 | $369.8K |
| 81450 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as blood or bone marrow, for DNA and possibly RNA alterations in five to 50 genes known to impact… | 390 | $740 | $286.8K |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 2,250 | $60 | $141.9K |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 1,970 | $50 | $102.3K |
| 88360 | The lab analyst applies a single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist, evaluates the… | 1,010 | $80 | $75.9K |
| 88189 | The clinician, typically a pathologist, interprets flow cytometry results of 16 or more markers. | 900 | $70 | $60.4K |
| 88313 | The lab analyst performs the technical lab steps to stain a specimen for Group II identification, for example an iron stain or trichrome stain. A qualified provider, typically a pathologist,… | 1,000 | $60 | $57.2K |
| 88368 | The lab analyst applies an initial in situ hybridization single probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a… | 520 | $110 | $55.2K |
Showing 1–10 of 58
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 58 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
58 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81450 | 2 | 10 | 230 | $740 | $833.5K |
| 88120 | 14 | 20 | 200 | $350 | $278K |
| 88185 | 4 | 20 | 690 | $20 | $265.7K |
| 81513 | 2 | 10 | 60 | $140 | $217.2K |
| 88377 | 3 | 20 | 30 | $240 | $205.5K |
| 81339 | 6 | 10 | 930 | $180 | $195.7K |
| 81279 | 9 | 10 | 850 | $180 | $157.2K |
| 81445 | 3 | 10 | 210 | $590 | $145.9K |
| 81206 | 5 | 10 | 390 | $160 | $122.1K |
| U0003 | 21 | 80 | 110 | $70 | $101.7K |
Showing 1–10 of 58
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
31 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 28,090 | $60 | $1.6M |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 20,100 | $30 | $683.3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 15,340 | $20 | $230K |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 9,400 | $20 | $178.6K |
| 88377 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a… | 470 | $150 | $72.4K |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 170 | $290 | $48K |
| 88312 | The lab analyst performs the technical lab steps to stain a specimen with a special stain. This code applies to Group I for microorganisms. A qualified provider, typically a pathologist, interprets… | 2,460 | $10 | $19.7K |
| 88313 | The lab analyst performs the technical lab steps to stain a specimen for Group II identification, for example an iron stain or trichrome stain. A qualified provider, typically a pathologist,… | 2,710 | $10 | $19K |
| 88189 | The clinician, typically a pathologist, interprets flow cytometry results of 16 or more markers. | 1,000 | $20 | $18.9K |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 510 | $30 | $14.4K |
Showing 1–10 of 31
How this provider's Medicaid billing volume and revenue compare to other New Jersey providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Jersey median
31 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 29 | 130 | 3,180 | $60 | $4.2M |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 11 | 20 | 750 | $10 | $1.3M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 82 | 120 | 900 | $20 | $971.9K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 79 | 120 | 940 | $20 | $957.4K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 35 | 50 | 400 | $10 | $839.8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 45 | 140 | 5,590 | $20 | $823.1K |
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 16 | 50 | 300 | $20 | $629.9K |
| 81513 | The lab analyst performs the technical lab test on a vaginal fluid specimen for quantitative real–time amplification of RNA markers for three bacterial species listed in the code descriptor, and… | 5 | 10 | 230 | $40 | $602.7K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 28 | 40 | 390 | $20 | $564.3K |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 10 | 20 | 410 | $180 | $462K |
Showing 1–10 of 31
Other providers in the same ZIP code as Neogenomics Laboratories Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Elite Medical Lab | NJ | Clinical Medical Laboratory | $157.8K | $13.3M |
| Rockland Surgical Project, LLC | NJ | Ambulatory Surgical Clinic/Center | $1.7M | $0 |
| Richard Lucanie | NJ | Internal Medicine Physician | $427.4K | $0 |
| Ali Seckin | NJ | Anesthesiology Physician | $414.3K | $0 |
| Steven Nickles | NJ | Family Medicine Physician | $400.8K | $0 |
| Anabel Lucanie | NJ | Internal Medicine Physician | $362.8K | $0 |
| Derek Berberian | NJ | Psychiatry Physician | $210.8K | $0 |
| Jocelyn Lieb | NJ | Dermatology Physician | $150.8K | $0 |
| Evan Chait | NJ | Physical Therapist | $137.9K | $0 |
| Michael Faust | NJ | Specialist | $30.2K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.